Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Accumulated Expenses: 2011-2024

Historic Accumulated Expenses for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $34.1 million.

  • Adma Biologics' Accumulated Expenses rose 4.69% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year increase of 4.69%. This contributed to the annual value of $34.1 million for FY2024, which is 3.60% up from last year.
  • Adma Biologics' Accumulated Expenses amounted to $34.1 million in FY2024, which was up 3.60% from $32.9 million recorded in FY2023.
  • Adma Biologics' 5-year Accumulated Expenses high stood at $34.1 million for FY2024, and its period low was $8.4 million during FY2020.
  • For the 3-year period, Adma Biologics' Accumulated Expenses averaged around $30.7 million, with its median value being $32.9 million (2023).
  • Data for Adma Biologics' Accumulated Expenses shows a peak YoY soared of 105.79% (in 2021) over the last 5 years.
  • Adma Biologics' Accumulated Expenses (Yearly) stood at $8.4 million in 2020, then soared by 105.79% to $17.2 million in 2021, then surged by 45.16% to $25.0 million in 2022, then skyrocketed by 31.73% to $32.9 million in 2023, then climbed by 3.60% to $34.1 million in 2024.